Indication
In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.

Medicine details

Medicine name:
lenvatinib (Kisplyx)
SMC ID:
SMC2199
Pharmaceutical company
Eisai Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
Q4 2019
SMC meeting date:
Q4 2019
Patient group submission deadline:
05 August 2019